1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Eli Lilly and Company

Eli Lilly and Company

LLY
Eli Lilly and CompanyUS flagNew York Stock Exchange
1,148.20
USD
-11.40
- -
1.08TMarket Cap
Eli Lilly and Company
LLY
(New York Stock Exchange)

Recent

price

1,148.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
20.87
21.8
19.72
20.7
17.66
18.06
19.28
18.99
20.91
23.31
25.65
29.69
30.04
37.94
50.19
72.64
89.09
Revenue per Share
4.58
3.9
3.57
4.19
2.15
2.18
2.49
-0.19
3.14
8.69
6.47
5.85
6.57
5.83
11.8
23
29.87
Basic EPS, GAAP
5.13
4.97
3.72
4.16
2.6
1.21
3.41
3.28
2.44
3.64
4.67
5.65
4.84
-3.5
0.46
6.65
15.16
Free Cash Flow per Basic Share
1.96
1.96
1.91
1.9
1.89
1.92
1.96
2.08
2.25
2.52
2.81
3.24
3.72
4.52
5.21
6
6.47
Dividend per Share
10.78
11.7
12.88
15.79
13.84
13.18
12.72
10.54
9.3
2.72
5.9
9.42
11.21
11.98
15.81
29.65
38
Book Value per Share
6.6
7.27
8.73
11.91
9.66
4.97
5.16
2.9
7
-8.03
-5.83
-2.73
-0.66
-1.19
2.51
15.77
7.76
Tangible Book Value per Share
1,106
1,114
1,146
1,117
1,111
1,105
1,101
1,052
1,028
958
957
954
950
899
898
897
894
Basic Weighted Avg Shares
23,076
24,286
22,603
23,113
19,616
19,959
21,222
19,974
21,493
22,320
24,540
28,318
28,541
34,124
45,043
65,179
79,666
Sales/Revenue/Turnover
29.35
26.01
22.19
24
16.97
18
17.31
20.03
26.92
25.94
28.36
26.99
29.01
30.26
37.83
45.56
49.72
Operating Margin (%)
1,328
1,374
1,462
1,446
1,379
1,428
1,497
1,567
1,609
1,233
1,324
1,548
1,522
1,527
1,767
1,997
2,099
Depreciation Expense
5,070
4,348
4,089
4,685
2,390
2,408
2,738
-204
3,232
8,318
6,194
5,582
6,245
5,240
10,590
20,640
26,711
Net Income, GAAP
22.31
18.73
24.4
20.45
20.32
13.68
18.86
103.75
14.39
11.93
14.33
9.32
8.25
20.05
16.48
19.79
20.49
Effective Tax Rate (%)
21.97
17.9
18.09
20.27
12.19
12.07
12.9
-1.02
15.04
37.27
25.24
19.71
21.88
15.36
23.51
31.67
33.53
Profit Margin (%)
7,739
5,317
4,649
4,188
2,187
4,344
4,115
4,666
8,662
1,934
4,980
3,400
896
-1,566
4,364
20,401
16,931
Working Capital
6,770
5,465
5,519
4,200
5,333
7,972
8,368
9,940
9,196
13,818
16,587
15,346
14,738
18,321
28,527
40,868
47,858
LT Debt
12,413
13,536
14,774
17,641
15,388
14,590
14,080
11,668
10,909
2,699
5,825
9,155
10,775
10,864
14,272
26,535
33,879
Total Equity
28.96
25.11
17.85
19.52
10.88
12.97
12.59
-0.6
20.9
25.67
29.05
28.27
28.34
25.98
33.89
40.74
40.9
Return on Invested Capital (%)
29.35
22.57
20.69
22.3
10.85
11.08
12.3
-0.86
14.79
44.21
32.16
24.31
24.69
17.84
26.76
35.3
36.53
Return on Capital (%)
46.2
33.49
28.89
28.92
14.49
16.09
19.16
-1.59
30.18
133.78
150.18
76.35
63.63
48.92
84.84
101.36
102.44
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,635
4,000
7,050
LT Borrowings
40,868
39,370
47,858
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
895
894
892
Market Capitalization
961,624
821,814
1,069,292

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
55,629
54,835
64,672
Cash, Cash Equivalents & STI
7,268
5,282
8,950
Accounts Receivable, Net
17,760
18,429
20,083
Inventories
13,744
14,529
16,793
Total Current Liabilities
35,228
36,634
47,741
Payables & Accruals
22,761
22,576
27,234
ST Debt
1,635
4,000
7,050
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.64%
38.59%
85.92%
Free Cash Flow
127.74%
212.97%
1,340.58%
Net Income, GAAP
-146.26%
36.58%
94.9%
Sales/Revenue/Turnover
13.43%
22.49%
44.7%
Total Cash Common Dividend
9.88%
14.91%
15.04%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8,768
11,303
11,439
13,533
45,043
2025
12,729
15,558
17,601
19,292
65,179
2026
19,799
22,974
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.49
3.3
1.08
4.91
11.8
2025
3.07
6.3
6.22
7.42
23
2026
8.28
7.96
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.3
1.3
1.3
1.3
5.21
2025
1.5
1.5
1.5
1.5
6
2026
1.73
1.73
- -
- -
- -
Similar Companies
Senores Pharmaceuticals Ltd. (SENORES.NS)
Bristol-Myers Squibb Company (BRM.DE)
Sanofi (SNYNF)
Sanofi (SNW.DE)
Tong Ren Tang Technologies Co. Ltd. (TGRNF)
Amgen Inc. (AMGN)
Business

Company News

Company News APIChatGPT

  • fool.com

    Great News for Eli Lilly Stock Investors

  • reuters.com

    Aspen sees Mounjaro Africa sales above $124 million in 2027

  • 247wallst.com

    Lilly's Record Stock Price Is Hiding an Even Bigger Opportunity

  • zacks.com

    Here's Why Eli Lilly (LLY) is a Strong Momentum Stock

  • gurufocus.com

    First Look: Apple Names New CEO, Dell Surges on AI, Ford Recalls

  • fool.com

    This New Zepbound Study Could Be Great News for Eli Lilly Investors

  • zacks.com

    Eli Lilly to Buy Immunology Biotech Merida Biosciences in $2.9B Deal

  • prnewswire.com

    Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference

  • gurufocus.com

    Lilly's $2.88 Billion Immunology Deal Starts in Phase 1

  • fool.com

    Eli Lilly Is Acquiring Merdia Biosciences for Up to $2.88 Billion. Here's What That Means for Investors.

  • cnbc.com

    Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers

  • gurufocus.com

    Eli Lilly Stock Falls After Pharma Giant Unveils $2.9 Billion Acquisition

  • proactiveinvestors.com

    Eli Lilly to buy Merida Biosciences for up to $2.88B, expanding immunology pipeline

  • zacks.com

    LLY's Mounjaro Gets FDA Nod to Cut Cardiovascular Risk in Diabetes

  • barrons.com

    Lilly to Buy This Autoimmune Drugmaker for $2.9 Billion in Cash. What It Means for the Stock.

  • wsj.com

    Eli Lilly to Buy Merida Biosciences For Up to $2.875 Billion

  • prnewswire.com

    New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity

  • reuters.com

    Eli Lilly to buy Merida Biosciences in $2.88 billion deal

  • prnewswire.com

    Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases

  • fool.com

    AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?